Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1406

1.

A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY).

Ninomiya K, Hata T, Yoshioka H, Ohashi K, Bessho A, Hosokawa S, Ishikawa N, Yamasaki M, Shibayama T, Aoe K, Kozuki T, Harita S, Ueda Y, Murakami T, Fujimoto N, Yanai H, Toyooka S, Takata M, Hotta K, Kiura K; HER2-CS Network.

Chest. 2019 May 6. pii: S0012-3692(19)30031-5. doi: 10.1016/j.chest.2019.01.011. [Epub ahead of print]

PMID:
31072612
2.

Effects of FABP7 on functional recovery after spinal cord injury in adult mice.

Senbokuya N, Yoshioka H, Yagi T, Owada Y, Kinouchi H.

J Neurosurg Spine. 2019 May 3:1-7. doi: 10.3171/2019.2.SPINE18844. [Epub ahead of print]

PMID:
31051461
3.

The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV.

Akamatsu H, Ninomiya K, Kenmotsu H, Morise M, Daga H, Goto Y, Kozuki T, Miura S, Sasaki T, Tamiya A, Teraoka S, Tsubata Y, Yoshioka H, Hattori Y, Imamura CK, Katsuya Y, Matsui R, Minegishi Y, Mizugaki H, Nosaki K, Okuma Y, Sakamoto S, Sone T, Tanaka K, Umemura S, Yamanaka T, Amano S, Hasegawa K, Morita S, Nakajima K, Maemondo M, Seto T, Yamamoto N.

Int J Clin Oncol. 2019 Jul;24(7):731-770. doi: 10.1007/s10147-019-01431-z. Epub 2019 May 2.

PMID:
31049758
4.

Corrigendum to "Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan" [Lung Cancer, 129 (March) (2019) 55-62].

Watanabe S, Yoshioka H, Sakai H, Hotta K, Takenoyama M, Yamada K, Sugawara S, Takiguchi Y, Hosomi Y, Tomii K, Niho S, Yamamoto N, Nishio M, Ohe Y, Kato T, Takahashi T, Kamada A, Suzukawa K, Omori Y, Enatsu S, Nakagawa K, Tamura T.

Lung Cancer. 2019 Jun;132:157-158. doi: 10.1016/j.lungcan.2019.04.010. Epub 2019 Apr 20. No abstract available.

5.

RNAi of the sesquiterpene cyclase gene for phytoalexin production impairs pre- and post-invasive resistance to potato blight pathogens.

Yoshioka M, Adachi A, Sato Y, Doke N, Kondo T, Yoshioka H.

Mol Plant Pathol. 2019 Apr 16. doi: 10.1111/mpp.12802. [Epub ahead of print]

PMID:
30990946
6.

Cyclin A is a reliable proliferation marker in endometrial cancer cell lines.

Horie K, Yamamoto H, Karube K, Takebayashi K, Yoshino H, Yoshioka H, Watanabe J.

Oncol Lett. 2019 May;17(5):4455-4462. doi: 10.3892/ol.2019.10135. Epub 2019 Mar 8.

7.

A stochastic differential game approach toward animal migration.

Yoshioka H.

Theory Biosci. 2019 Apr 11. doi: 10.1007/s12064-019-00292-4. [Epub ahead of print]

PMID:
30972714
8.

Structure-activity relationship study of estrogen receptor down-regulators with a diphenylmethane skeleton.

Nanjyo S, Ohgane K, Yoshioka H, Makishima M, Hashimoto Y, Noguchi-Yachide T.

Bioorg Med Chem. 2019 May 15;27(10):1952-1961. doi: 10.1016/j.bmc.2019.03.042. Epub 2019 Mar 26.

PMID:
30940565
9.

A phase I/II trial of weekly nab-paclitaxel for pretreated non-small-cell lung cancer patients without epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangement.

Harada D, Kozuki T, Nogami N, Bessho A, Hosokawa S, Fukamatsu N, Hotta K, Ohashi K, Kubo T, Yoshioka H, Yokoyama T, Sone N, Kuyama S, Kudo K, Yasugi M, Takigawa N, Oze I, Kiura K.

Asia Pac J Clin Oncol. 2019 Apr 1. doi: 10.1111/ajco.13147. [Epub ahead of print]

PMID:
30938103
10.

Diverse functions of the thrombopoietin receptor agonist romiplostim rescue individuals exposed to lethal radiation.

Yamaguchi M, Hirouchi T, Yoshioka H, Watanabe J, Kashiwakura I.

Free Radic Biol Med. 2019 May 20;136:60-75. doi: 10.1016/j.freeradbiomed.2019.03.023. Epub 2019 Mar 26.

PMID:
30926566
11.

Possible cross-feeding pathway of facultative methylotroph Methyloceanibacter caenitepidi Gela4 on methanotroph Methylocaldum marinum S8.

Takeuchi M, Ozaki H, Hiraoka S, Kamagata Y, Sakata S, Yoshioka H, Iwasaki W.

PLoS One. 2019 Mar 14;14(3):e0213535. doi: 10.1371/journal.pone.0213535. eCollection 2019.

12.

Carboplatin Plus Nab-paclitaxel in Performance Status 2 Patients With Advanced Non-small-cell Lung Cancer.

Nakashima K, Akamatsu H, Murakami H, Niwa T, Iwamoto Y, Ozawa Y, Yokoyama T, Shoda H, Yamamoto N, Yoshioka H, Masuda K, Naito T, Mori K, Takahashi T.

Anticancer Res. 2019 Mar;39(3):1463-1468. doi: 10.21873/anticanres.13263.

PMID:
30842183
13.

Efficacy of Intraarterial Fluorescence Video Angiography in Surgery for Dural and Perimedullary Arteriovenous Fistula at Craniocervical Junction.

Kanemaru K, Yoshioka H, Hashimoto K, Murayama H, Ogiwara M, Yagi T, Horikoshi T, Kinouchi H.

World Neurosurg. 2019 Mar 1. pii: S1878-8750(19)30508-X. doi: 10.1016/j.wneu.2019.02.097. [Epub ahead of print]

PMID:
30831279
14.

Long-Term Clinical and Angiographic Outcomes of Wrap-Clipping for Ruptured Blood Blister-Like Aneurysms of the Internal Carotid Artery Using Advanced Monitoring.

Hanihara M, Yoshioka H, Kanemaru K, Hashimoto K, Shimizu M, Nishigaya K, Fukamachi A, Kinouchi H.

World Neurosurg. 2019 Feb 28. pii: S1878-8750(19)30481-4. doi: 10.1016/j.wneu.2019.02.070. [Epub ahead of print]

PMID:
30825634
15.

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan.

Watanabe S, Yoshioka H, Sakai H, Hotta K, Takenoyama M, Yamada K, Sugawara S, Takiguchi Y, Hosomi Y, Tomii K, Niho S, Yamamoto N, Nishio M, Ohe Y, Kato T, Takahashi T, Kamada A, Suzukawa K, Omori Y, Enatsu S, Nakagawa K, Tamura T.

Lung Cancer. 2019 Mar;129:55-62. doi: 10.1016/j.lungcan.2019.01.005. Epub 2019 Jan 16. Erratum in: Lung Cancer. 2019 Jun;132:157-158.

16.

Usefulness of Cytological Scoring Method by Breast Fine Needle Aspiration Cytology on Breast Duct Dilatation and Cystic Lesions.

Yoshioka H, Ueno H, Oikawa S, Tanaka M, Hasegawa Y, Horie K, Watanabe J.

J Cytol. 2019 Jan-Mar;36(1):53-58. doi: 10.4103/JOC.JOC_135_17.

17.

A simplified stochastic optimization model for logistic dynamics with control-dependent carrying capacity.

Yoshioka H.

J Biol Dyn. 2019 Dec;13(1):148-176. doi: 10.1080/17513758.2019.1576927.

PMID:
30727850
18.

Non-small cell lung cancer with pathological complete response: predictive factors and surgical outcomes.

Kayawake H, Okumura N, Yamanashi K, Takahashi A, Itasaka S, Yoshioka H, Nakashima T, Matsuoka T.

Gen Thorac Cardiovasc Surg. 2019 Feb 6. doi: 10.1007/s11748-019-01076-9. [Epub ahead of print]

PMID:
30725275
19.

Inhibition of the Inflammatory Pathway Enhances Both the in Vitro and in Vivo Transfection Activity of Exogenous in Vitro-Transcribed mRNAs Delivered by Lipid Nanoparticles.

Ohto T, Konishi M, Tanaka H, Onomoto K, Yoneyama M, Nakai Y, Tange K, Yoshioka H, Akita H.

Biol Pharm Bull. 2019;42(2):299-302. doi: 10.1248/bpb.b18-00783.

20.

Demonstration of on-chip quantum dot microcavity lasers in a molecularly engineered annular groove.

Chen C, Yuan J, Wan L, Chandrahalim H, Chen Z, Nishimura N, Takeda H, Yoshioka H, Liu W, Oki Y, Fan X, Li Z.

Opt Lett. 2019 Feb 1;44(3):495-498. doi: 10.1364/OL.44.000495.

PMID:
30702662
21.

Pembrolizumab-induced autoimmune encephalitis in a patient with advanced non-small cell lung cancer: A case report.

Niki M, Nakaya A, Kurata T, Nakahama K, Yoshioka H, Kaneda T, Kibata K, Ogata M, Nomura S.

Mol Clin Oncol. 2019 Feb;10(2):267-269. doi: 10.3892/mco.2018.1777. Epub 2018 Nov 27.

22.

KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer.

Nishio M, Takahashi T, Yoshioka H, Nakagawa K, Fukuhara T, Yamada K, Ichiki M, Tanaka H, Seto T, Sakai H, Kasahara K, Satouchi M, Han SR, Noguchi K, Shimamoto T, Kato T.

Cancer Sci. 2019 Mar;110(3):1012-1020. doi: 10.1111/cas.13932. Epub 2019 Feb 16.

23.

Phase II Study of Weekly Amrubicin for Refractory or Relapsed Non-small Cell Lung Cancer.

Kitagawa C, Iwasaku M, Kogure Y, Ando M, Yoshioka H, Nishiyama A, Watanabe N, Kunimasa K, Tsubouchi K, Oka S, Saka H.

In Vivo. 2019 Jan-Feb;33(1):163-166. doi: 10.21873/invivo.11453.

24.

New scoring system in assessment of Hoffa's fat pad synovitis: A comparative study with established scoring systems.

Hagiwara S, Yang A, Takao S, Kaneko Y, Nozaki T, Yoshioka H.

World J Radiol. 2018 Nov 28;10(11):162-171. doi: 10.4329/wjr.v10.i11.162.

25.

The delivery of mRNA to colon inflammatory lesions by lipid-nano-particles containing environmentally-sensitive lipid-like materials with oleic acid scaffolds.

Tanaka H, Watanabe A, Konishi M, Nakai Y, Yoshioka H, Ohkawara T, Takeda H, Harashima H, Akita H.

Heliyon. 2018 Dec 3;4(12):e00959. doi: 10.1016/j.heliyon.2018.e00959. eCollection 2018 Dec.

26.

Pseudoprogression in Previously Treated Patients with Non-Small Cell Lung Cancer Who Received Nivolumab Monotherapy.

Fujimoto D, Yoshioka H, Kataoka Y, Morimoto T, Hata T, Kim YH, Tomii K, Ishida T, Hirabayashi M, Hara S, Ishitoko M, Fukuda Y, Hwang MH, Sakai N, Fukui M, Nakaji H, Morita M, Mio T, Yasuda T, Sugita T, Hirai T.

J Thorac Oncol. 2019 Mar;14(3):468-474. doi: 10.1016/j.jtho.2018.10.167. Epub 2018 Nov 20.

PMID:
30468872
27.

Phase II Study of Weekly Amrubicin for Refractory or Relapsed Small Cell Lung Cancer.

Yoshioka H, Kogure Y, Ando M, Kitagawa C, Iwasaku M, Niwa T, Saka H.

In Vivo. 2018 Nov-Dec;32(6):1581-1586. doi: 10.21873/invivo.11417.

28.

Neuroprotective effects of microglial P2Y1 receptors against ischemic neuronal injury.

Fukumoto Y, Tanaka KF, Parajuli B, Shibata K, Yoshioka H, Kanemaru K, Gachet C, Ikenaka K, Koizumi S, Kinouchi H.

J Cereb Blood Flow Metab. 2018 Oct 18:271678X18805317. doi: 10.1177/0271678X18805317. [Epub ahead of print]

PMID:
30334687
29.

1O, 20O-diacetyl kamebakaurin protects against acetaminophen-induced hepatotoxicity in mice.

Yoshioka H, Nonogaki T, Ohnishi H, Fukuishi N, Yoshikawa M, Gui MY, Jin YR, Li XW, Adachi Y, Ohno N, Takeya K, Hitotsuyanagi Y, Miura N, Aoyagi Y.

Biomed Res. 2018;39(5):251-260. doi: 10.2220/biomedres.39.251.

30.

Excessive hair growth in a patient with psoriatic erythroderma following secukinumab administration.

Mashima E, Sawada Y, Yamaguchi T, Yoshioka H, Ohmori S, Haruyama S, Okada E, Nakamura M.

Eur J Dermatol. 2018 Aug 1;28(4):539-540. doi: 10.1684/ejd.2018.3327. No abstract available.

PMID:
30325327
31.

Stochastic differential game for management of non-renewable fishery resource under model ambiguity.

Yoshioka H, Yaegashi Y.

J Biol Dyn. 2018 Dec;12(1):817-845. doi: 10.1080/17513758.2018.1528394.

PMID:
30325271
32.

Sasa veitchii extract protects against carbon tetrachloride-induced hepatic fibrosis in mice.

Yoshioka H, Nonogaki T, Fukaya S, Ichimaru Y, Nagatsu A, Yoshikawa M, Fujii H, Nakao M.

Environ Health Prev Med. 2018 Oct 15;23(1):49. doi: 10.1186/s12199-018-0739-7.

33.

Embolization of a peripheral cerebral aneurysm associated with intracranial major artery occlusion through a transdural anastomotic artery: Case report.

Fukuda N, Kanemaru K, Hashimoto K, Yoshioka H, Senbokuya N, Yagi T, Kinouchi H.

Interv Neuroradiol. 2019 Apr;25(2):172-176. doi: 10.1177/1591019918801539. Epub 2018 Sep 19.

PMID:
30231796
34.

Profile fluctuation of peripheral blood in advanced melanoma patients treated with nivolumab.

Saito R, Sawada Y, Saito-Sasaki N, Yamamoto K, Yoshioka H, Ohmori S, Yoshioka M, Okada E, Nakamura M.

J Dermatol. 2018 Dec;45(12):1452-1455. doi: 10.1111/1346-8138.14643. Epub 2018 Sep 11.

PMID:
30204257
35.

Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer.

Niki M, Nakaya A, Kurata T, Yoshioka H, Kaneda T, Kibata K, Ogata M, Nomura S.

Oncotarget. 2018 Aug 17;9(64):32298-32304. doi: 10.18632/oncotarget.25949. eCollection 2018 Aug 17.

36.

DNA-loaded nano-adjuvant formed with a vitamin E-scaffold intracellular environmentally-responsive lipid-like material for cancer immunotherapy.

Kawai M, Nakamura T, Miura N, Maeta M, Tanaka H, Ueda K, Higashi K, Moribe K, Tange K, Nakai Y, Yoshioka H, Harashima H, Akita H.

Nanomedicine. 2018 Nov;14(8):2587-2597. doi: 10.1016/j.nano.2018.08.006. Epub 2018 Aug 29.

PMID:
30170077
37.

Surgical outcomes and complications of pneumonectomy after induction therapy for non-small cell lung cancer.

Kayawake H, Okumura N, Yamanashi K, Otsuki Y, Takahashi A, Itasaka S, Yoshioka H, Nakashima T, Matsuoka T.

Gen Thorac Cardiovasc Surg. 2018 Nov;66(11):658-663. doi: 10.1007/s11748-018-0980-4. Epub 2018 Aug 6.

PMID:
30083866
38.

Microbial community structure in deep natural gas-bearing aquifers subjected to sulfate-containing fluid injection.

Katayama T, Yoshioka H, Yamanaka T, Takeuchi M, Muramoto Y, Usami J, Ikeda H, Sakata S.

J Biosci Bioeng. 2019 Jan;127(1):45-51. doi: 10.1016/j.jbiosc.2018.06.013. Epub 2018 Aug 3.

PMID:
30082219
39.

Development of an Alcohol Dilution-Lyophilization Method for Preparing Lipid Nanoparticles Containing Encapsulated siRNA.

Shirane D, Tanaka H, Nakai Y, Yoshioka H, Akita H.

Biol Pharm Bull. 2018;41(8):1291-1294. doi: 10.1248/bpb.b18-00208.

40.

Expression levels of brown/beige adipocyte-related genes in fat depots of vitamin A-restricted fattening cattle.

Chen HJ, Ihara T, Yoshioka H, Itoyama E, Kitamura S, Nagase H, Murakami H, Hoshino Y, Murakami M, Tomonaga S, Matsui T, Funaba M.

J Anim Sci. 2018 Jun 15. doi: 10.1093/jas/sky240. [Epub ahead of print]

PMID:
29912360
41.

Potentiating effect of acetaminophen and carbon tetrachloride-induced hepatotoxicity is mediated by activation of receptor interaction protein in mice.

Yoshioka H, Ichimaru Y, Fukaya S, Nagatsu A, Nonogaki T.

Toxicol Mech Methods. 2018 Oct;28(8):615-621. doi: 10.1080/15376516.2018.1485804. Epub 2018 Aug 2.

PMID:
29873576
42.

Intragenic copy number variation within human epiplakin 1 (EPPK1) generates variation of molecular size of epiplakin.

Ishikawa K, Furuhashi M, Sasaki T, Kudoh J, Tsuchisaka A, Hashimoto T, Sasaki T, Yoshioka H, Eshima N, Matsuda-Hirose H, Sakai T, Hatano Y, Fujiwara S.

J Dermatol Sci. 2018 May 24. pii: S0923-1811(18)30234-2. doi: 10.1016/j.jdermsci.2018.05.008. [Epub ahead of print] No abstract available.

PMID:
29866520
43.

Alopecia Areata-like Hair Loss Accompanying Toxic Epidermal Necrolysis.

Mashima E, Sawada Y, Inoue A, Saito-Sasaki N, Yamaguchi T, Yoshioka H, Ohmori S, Haruyama S, Yoshioka M, Okada E, Nakamura M.

Acta Derm Venereol. 2018 Oct 10;98(9):906-907. doi: 10.2340/00015555-2982. No abstract available.

44.

Model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients.

Yoshioka H, Sato H, Hatakeyama H, Hisaka A.

Blood Adv. 2018 May 22;2(10):1066-1075. doi: 10.1182/bloodadvances.2017013805.

45.

Novel valosin-containing protein mutations associated with multisystem proteinopathy.

Al-Tahan S, Al-Obeidi E, Yoshioka H, Lakatos A, Weiss L, Grafe M, Palmio J, Wicklund M, Harati Y, Omizo M, Udd B, Kimonis V.

Neuromuscul Disord. 2018 Jun;28(6):491-501. doi: 10.1016/j.nmd.2018.04.007. Epub 2018 Apr 17.

PMID:
29754758
46.

A singular stochastic control model for sustainable population management of the fish-eating waterfowl Phalacrocorax carbo.

Yaegashi Y, Yoshioka H, Unami K, Fujihara M.

J Environ Manage. 2018 Aug 1;219:18-27. doi: 10.1016/j.jenvman.2018.04.099. Epub 2018 Apr 30.

PMID:
29723745
47.

An optimal stopping approach for onset of fish migration.

Yoshioka H, Yaegashi Y.

Theory Biosci. 2018 Nov;137(2):99-116. doi: 10.1007/s12064-018-0263-8. Epub 2018 May 2.

PMID:
29721787
48.

A hepatic pDNA delivery system based on an intracellular environment sensitive vitamin E-scaffold lipid-like material with the aid of an anti-inflammatory drug.

Togashi R, Tanaka H, Nakamura S, Yokota H, Tange K, Nakai Y, Yoshioka H, Harashima H, Akita H.

J Control Release. 2018 Jun 10;279:262-270. doi: 10.1016/j.jconrel.2018.04.022. Epub 2018 Apr 17.

PMID:
29673647
49.

Assessing patterns of T2/T1rho change in grade 1 cartilage lesions of the distal femur using an angle/layer dependent approach.

Kaneko Y, Nozaki T, Yu H, Schwarzkopf R, Hara T, Yoshioka H.

Clin Imaging. 2018 Jul - Aug;50:201-207. doi: 10.1016/j.clinimag.2018.03.017. Epub 2018 Apr 7.

PMID:
29660530
50.

Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study.

Fujimoto D, Yoshioka H, Kataoka Y, Morimoto T, Kim YH, Tomii K, Ishida T, Hirabayashi M, Hara S, Ishitoko M, Fukuda Y, Hwang MH, Sakai N, Fukui M, Nakaji H, Morita M, Mio T, Yasuda T, Sugita T, Hirai T.

Lung Cancer. 2018 May;119:14-20. doi: 10.1016/j.lungcan.2018.02.017. Epub 2018 Mar 2.

PMID:
29656747

Supplemental Content

Loading ...
Support Center